Lv68
2520 积分 2025-10-26 加入
Anticoagulation therapy for patients with atrial fibrillation at primary care facilities in Beijing, China, 2017–2022
19小时前
已关闭
Asundexian versus Apixaban in Patients with Atrial Fibrillation
19小时前
待确认
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
19小时前
待确认
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials
19小时前
待确认
Variation and disparity in awareness of atrial fibrillation in China: A national cross-sectional study
19小时前
待确认
Epidemiology, management, and outcomes of atrial fibrillation among 30 million citizens in Shanghai, China from 2015 to 2020: A medical insurance database study
20小时前
已关闭
Discovering small-molecule senolytics with deep neural networks
3天前
已完结
Can AI Say “I Don’t Know”?
6天前
已完结
Asundexian versus Apixaban in Patients with Atrial Fibrillation
11天前
已完结
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
11天前
已完结
皖公网安备34019202002308
